Survival after curative surgical treatment for primary oral squamous cell carcinoma

Bloebaum, Monique; Poort, Linda; Böckmann, Roland; Keßler, Peter

doi:10.1016/j.jcms.2014.01.046

Cited by 54 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5‐year OS rate of our patient population was 81%. This value is higher as most survival rates described by other authors, which range between 41% and 70% (Bloebaum, Poort, Böckmann, & Kessler, 2014; Gil et al., 2009; González‐García et al., 2009; Jardim, Francisco, Gondak, Damascena, & Kowalski, 2015; Ong, Murphy, Smith, Kanatas, & Mitchell, 2017; Rogers et al., 2009; Wong et al., 2012; Zanoni et al., 2019). The 5‐year DFS and 5‐year LRC rate were 66% and 75%, respectively.…”

Section: Discussioncontrasting

confidence: 47%

See 1 more Smart Citation

Survival outcomes after surgical treatment of oral squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective To identify the clinicopathological parameters that influence survival in patients with oral squamous cell carcinoma, in order to allow for the development of individualized surveillance programmes and reduce the delay in diagnosis of recurrence. Materials and Methods Retrospective chart review of 553 patients with a treatment‐naïve primary oral squamous cell carcinoma, who underwent primarily curative intended surgery. Exclusion criteria were neoadjuvant radio(chemo)therapy, follow‐up < 1 year, perioperative death, inoperable disease, synchronous multiple malignancies and inadequate information on clinicopathological parameters. Results The clinicopathological factors that influence overall survival, disease‐free survival and locoregional control were calculated. In the multivariate survival analysis, the occurrence of recurrence, presence of extracapsular spread, T‐ and N‐classification were shown to be independent risk factors for overall survival. Conclusion The identification of these risk factors can lead to the development of individualized follow‐up programmes based on risk stratification. This allows for the earliest possible diagnosis of relapse which is essential to offer the patient a realistic second treatment chance and to improve survival rates.

show abstract

Section: Discussioncontrasting

confidence: 47%

“…The 5‐year DFS and 5‐year LRC rate were 66% and 75%, respectively. These rates are as well slightly higher as most reported rates (Bloebaum et al., 2014; Jardim et al., 2015; Rogers et al., 2009; Vázquez‐Mahía et al., 2012). However, interdata comparison is difficult because of different inclusion criteria in different studies.…”

Section: Discussionmentioning

confidence: 46%

Survival outcomes after surgical treatment of oral squamous cell carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Oral cancer is life‐threatening because of its invasion of critical structures responsible for speaking, swallowing, and respiration . The treatment of oral cancer has advanced considerably from surgery to a comprehensive sequential treatment that include surgery in combination with chemoradiotherapy; however, the 5‐year survival rate has not significantly improved in recent decades, primarily because of its extreme malignancy, including local metastasis, and high recurrence potential . Thus, more substantial efforts have stimulated in developing more effective treatments in order to improve the survival rate.…”

mentioning

confidence: 99%

An adaptive immune response driven by mature, antigen‐experienced T and B cells within the microenvironment of oral squamous cell carcinoma

Quan

Fang

Pān

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Lymphocyte infiltrates have been observed in the microenvironment of oral cancer; however, little is known about whether the immune response of the lymphocyte infiltrate affects tumor biology. For a deeper understanding of the role of the infiltratinglymphocytes in oral squamous cell carcinoma (OSCC), we characterized the lymphocyte infiltrate repertoires and defined their features. Immunohistochemistry revealed considerable T and B cell infiltrates and lymphoid follicles with germinal center-like structures within the tumor microenvironment. Flow cytometry demonstrated that populations of antigen-experienced CD41 and CD81 cells were present, as well as an enrichment of regulatory T cells; and T cells expressing programmed death-1 (PD-1) and T cell Ig and mucin protein-3 (Tim-3), indicative of exhaustion, within the tumor microenvironment. Characterization of tumorinfiltrating B cells revealed clear evidence of antigen exposure, in that the cardinal features of an antigen-driven B cell response were present, including somatic mutation, clonal expansion, intraclonal variation and isotype switching. Collectively, our results point to an adaptive immune response occurring within the OSCC microenvironment, which may be sustained by the expression of specific antigens in the tumor.Oral cancer is the sixth most common cancer in the world, most of which is oral squamous cell carcinoma (OSCC), accounting for 3% of all malignancies and increasing by 275,000 new cases per year.1,2 Oral cancer is life-threatening because of its invasion of critical structures responsible for speaking, swallowing, and respiration. 3 The treatment of oral cancer has advanced considerably from surgery to a comprehensive sequential treatment that include surgery in combination with chemoradiotherapy; however, the 5-year survival rate has not significantly improved in recent decades, primarily because of its extreme malignancy, including local metastasis, and high recurrence potential. 3,4 Thus, more substantial efforts have stimulated in developing more effective treatments in order to improve the survival rate. Due to the progress in the field of tumor immunology, immunotherapy emerges as a promising option. 5,6The immune response between host and tumor is extremely complex. The function of immune system is to eliminate alien cells; however within the tumor microenvironment, tumor cells escape the immune surveillance and

show abstract

“…This is a significant source of anxiety for head and neck cancer patients, even among long‐term survivors . Early diagnosis is vital for head and neck oncologists because treating patients with recurrent disease is a challenge and outcomes are worse compared to primary treatment . This article will focus on the current NCCN guidelines for management of patients who present with recurrent/persistent head and neck cancer.…”

Section: Introductionmentioning

confidence: 99%

AHNS series: Do you know your guidelines? Guideline recommendations for recurrent and persistent head and neck cancer after primary treatment

2018

View full text Add to dashboard Cite

Locoregional recurrent/persistent head and neck cancer following primary treatment is a significant challenge as it is usually difficult to treat and has worse outcomes compared to the primary setting. Surgical resection of a local or regional recurrence offers the best chance of cure when feasible. Local recurrence outcomes vary by subsite with laryngeal recurrences having the best prognoses and hypopharynx having the worst. Instances of persistent neck masses following primary nonsurgical treatment can be evaluated with positron emission tomography (PET) with CT (PET-CT) when there is no definitive diagnosis of a recurrence/persistence. Reirradiation with or without chemotherapy can be considered for primary treatment when surgery is not an option, for adjuvant treatment following salvage surgery, or for palliation. Immunotherapy represents a newer class of chemotherapeutic agents. Current guidelines recommend enrollment in clinical trials especially when surgery is not an option as outcomes remain universally poor in the recurrent/persistent setting.

show abstract

Survival after curative surgical treatment for primary oral squamous cell carcinoma

Cited by 54 publications

References 26 publications

Survival outcomes after surgical treatment of oral squamous cell carcinoma

Survival outcomes after surgical treatment of oral squamous cell carcinoma

An adaptive immune response driven by mature, antigen‐experienced T and B cells within the microenvironment of oral squamous cell carcinoma

AHNS series: Do you know your guidelines? Guideline recommendations for recurrent and persistent head and neck cancer after primary treatment

Contact Info

Product

Resources

About